The Phoenix Trial
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - (PHOENIX)
*Enrollment is now closed. We will keep you updated on the results of this study as they are published.
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in patients with rare forms of chronic kidney disease.
Trial for people with
Primary Membranous Nephropathy (MN), IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G)
Patients will be enrolled in disease specific cohorts within the trial, and effectiveness of bardoxolone methyl in treating kidney disease will be assessed separately by cohort for each rare CKD.
What is involved for the Patient?
Participation in PHOENIX may last up to 16 weeks, and will include 10 study visits and 6 scheduled phone calls.
About the drug or intervention
Bardoxolone Methyl is an oral medication that inhibits an inflammatory pathway in the body.
- Study CoordinatorLarry Stonesifer
- Study Coordinator Emailpatientadvocate@nephcure.org
- Study Coordinator Phone(253)927-4777
- Site NameLarry Stonesifer
- SponsorReata Pharmaceuticals, Inc.
- Study Drugbardoxolone
- Estimated enrollment100
- Estimated end dateJuly, 2019